Stocks · Healthcare · Biotechnology
Twist Bioscience Corporation TWST
$188.67 +0.33% Close, Oct 2, 2026 · NASDAQ · Market cap $11.75B
Strong growthStrong trend
Next earnings report: Nov 13, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Over the past year the stock returned +544.8%, ahead of the S&P 500 by 529.7 percentage points.
- Operating margin widened to -31.9% from -39.3% a year earlier.
- The stock is in an uptrend: above its 200-day average for 188 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 34%
- Revenue growth, 3-year CAGRTop 28%
- Revenue growth accelerationTop 33%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 47%
- Gross marginBottom 36%
- Operating marginBottom 39%
- Accruals (lower is better)Top 28%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 33%
- Free-cash-flow yieldTop 38%
- EBITDA / enterprise valueTop 40%
- Sales / enterprise valueBottom 18%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 3%
- 6-month returnTop 1%
- 1-year return vs S&P 500Top 1%
- Distance from 52-week highTop 7%
- Trend checklist (0–4)Top 7%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 27%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 44%
- Upside to consensus price targetBottom 2%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 13%
- Maximum drawdown, 3 yearsTop 33%
- Beta vs S&P 500 (lower is better)Bottom 29%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 17.8% | 19.2% | ↑ |
| Gross margin | 49.2% | 52.0% | ↑ |
| Operating margin | -39.3% | -31.9% | ↑ |
| FCF margin | -19.0% | -21.6% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 19.2% | 17.8% | ↑ | Top 34% |
| Gross margin | 52.0% | 49.2% | ↑ | Bottom 36% |
| Operating margin | -31.9% | -39.3% | ↑ | Bottom 39% |
| Net margin | -31.7% | -23.5% | ↓ | — |
| Free-cash-flow margin | -21.6% | -19.0% | ↓ | — |
| Return on invested capital | -24.6% | — | Bottom 47% | |
| Revenue growth, 3-year CAGR | 22.8% | — | Top 28% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -12.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 15.4%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +12.7 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.07%
- Shareholder yield
- -0.07%
- Share count change, 1 year
- +2.0%
- Share count change, 3-year CAGR
- +3.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 3, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -12.4%
- Average 2-day reaction, last 8
- +0.2%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $131.33
- Target vs current price
- -30.4%
- Analysts with a rating
- 15
- Share rating Buy or Strong Buy
- 73%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 3, 2026 | -10.6% | +10.4% | +26.3% | +54.4% | — |
| May 4, 2026 | -44.9% | -7.0% | -5.9% | +12.4% | +41.5% |
| Feb 2, 2026 | -4.2% | +14.0% | +19.9% | +11.7% | +44.0% |
| Nov 14, 2025 | +10.0% | -10.1% | -12.8% | +3.4% | +66.0% |
| Aug 4, 2025 | +13.0% | -10.3% | -23.9% | -19.9% | +1.5% |
| May 5, 2025 | -17.9% | -8.4% | -21.5% | -20.8% | -11.5% |
| Feb 3, 2025 | +14.5% | +0.7% | -0.1% | -29.1% | -24.2% |
| Nov 18, 2024 | +17.4% | +12.3% | +14.5% | +31.3% | +29.0% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 3, 2026 | -$0.56 | -$0.51 | -10.6% | $118.4M |
| May 4, 2026 | -$0.71 | -$0.49 | -44.9% | $110.7M |
| Feb 2, 2026 | -$0.50 | -$0.48 | -4.2% | $103.7M |
| Nov 14, 2025 | -$0.45 | -$0.50 | +10.0% | $99.0M |
| Aug 4, 2025 | -$0.47 | -$0.54 | +13.0% | $96.1M |
| May 5, 2025 | -$0.66 | -$0.56 | -17.9% | $92.8M |
| Feb 3, 2025 | -$0.53 | -$0.62 | +14.5% | $88.7M |
| Nov 18, 2024 | -$0.59 | -$0.71 | +17.4% | $84.7M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 27.15× | — | — | Bottom 18% |
| Free-cash-flow yield | -0.79% | — | — | Top 38% |
| Earnings yield | -1.18% | — | — | Top 33% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 94
- Days above the 200-day average
- 188
- 50-day average slope (20 days)
- +23.0%
- 200-day average slope (20 days)
- +19.9%
- Distance from 50-day average
- +39.0%
- Distance from 200-day average
- +144.8%
- RSI (14)
- 70.7
- Relative volume
- 0.92×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 88.3%
- Volatility vs own 5-year history
- 82th percentile · High for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.59
- Correlation with S&P 500
- 0.33
- Current drawdown from 1-year high
- -2.4%
- Maximum drawdown, 3 years
- -59.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 20, 2021 | May 2, 2023 | -94.5% | 574 days | Not yet recovered |
| Oct 15, 2020 | Oct 30, 2020 | -23.3% | 11 days | 8 days (Nov 11, 2020) |
| Dec 22, 2020 | Jan 4, 2021 | -20.8% | 7 days | 5 days (Jan 11, 2021) |
| Nov 23, 2020 | Nov 25, 2020 | -15.0% | 2 days | 3 days (Dec 1, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $11.75B
- EPS, diluted (TTM)
- -$2.22
- Revenue (TTM)
- $431.8M
- 52-week range
- $23.30 – $200.31
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $132.3M | $203.6M | $245.1M | $313.0M | $376.6M |
| Gross profit | $51.7M | $84.2M | $89.7M | $133.3M | $191.0M |
| Operating income | -$152.7M | -$234.8M | -$217.2M | -$220.8M | -$136.3M |
| Net income | -$152.1M | -$217.9M | -$204.6M | -$208.7M | -$77.7M |
| EPS (diluted) | -$3.15 | -$4.04 | -$3.60 | -$3.60 | -$1.30 |
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84.7M | $88.7M | $92.8M | $96.1M | $99.0M | $103.7M | $110.7M | $118.4M |
| Net income | -$34.7M | -$31.6M | -$39.3M | $20.4M | -$27.1M | -$30.5M | -$44.0M | -$35.1M |
| EPS (diluted) | -$0.60 | -$0.53 | -$0.66 | $0.33 | -$0.45 | -$0.50 | -$0.71 | -$0.56 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$112.2M | -$124.4M | -$142.5M | -$64.1M | -$47.6M |
| Capital expenditure | -$27.1M | -$101.9M | -$27.8M | -$5.1M | -$28.0M |
| Free cash flow | -$139.3M | -$226.2M | -$170.3M | -$69.2M | -$75.6M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $313.0M | $262.1M | -$4.4M | -$4.0M | $13.5M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $166.8M
- Total assets
- $672.4M
- Total liabilities
- $226.7M
- Total debt
- $93.6M
- Net debt
- -$23.8M
- Shareholders’ equity
- $445.7M
As of Jun 30, 2026 (filed Aug 3, 2026).
Short interest
- Shares sold short
- 12,505,220
- Days to cover
- 8.92
- Change vs previous report
- +3.6%
FINRA short interest, settlement date Sep 15, 2026.